Key Points
Abbott reaches $384 million settlement
Abbott Laboratories (ABT) has agreed to pay $384 million to resolve U.S. government allegations related to its infant formula manufacturing. The settlement addresses civil claims that the company supplied infant formula to federal and state programs that was produced in environments posing a substantial risk of contamination.
The Justice Department stated that payments for these products came from funds administered by the U.S. Department of Agriculture and Medicaid. These programs help finance nutrition and health services, making the source of the funds a central element of the government’s civil claims.
Focus on manufacturing conditions and facilities
Government allegations center on Abbott knowingly manufacturing infant formula in conditions that increased the risk of contamination. Authorities asserted that the company nonetheless sold these products into programs funded by federal and state agencies.
The settlement documentation references Abbott production plants in Sturgis, Michigan, and Casa Grande, Arizona. These facilities were identified as the locations tied to the alleged manufacturing conditions that gave rise to the civil claims.
Resolution of civil and criminal matters
Abbott stated that the settlement was reached without any determination of liability. As part of the agreement, the company did not admit wrongdoing in connection with the allegations over its infant formula production.
The company also indicated that a related criminal investigation was closed. With the civil settlement in place and the criminal probe no longer active, the agreement marks a significant step in resolving federal scrutiny of Abbott’s infant formula manufacturing practices.
Implications for federal and state programs
By resolving claims tied to products funded through the U.S. Department of Agriculture and Medicaid, the settlement directly affects key federal and state programs. The government’s allegations highlighted concerns about how public funds were used to purchase infant formula produced under questioned manufacturing conditions.
The $384 million payment concludes the federal government’s civil claims linked to these allegations, while leaving Abbott’s formal legal position unchanged due to the absence of an admission of liability. The outcome underscores both the financial scale of the resolution and the regulatory focus on product safety in publicly funded nutrition programs.
Key Takeaways
- 01The settlement ends major U.S. civil claims over Abbott’s infant formula practices while leaving the company’s legal liability formally unresolved.
- 02Federal scrutiny centered on whether infant formula bought with USDA and Medicaid funds was produced in environments that raised contamination risks.
- 03By tying allegations to specific plants in Michigan and Arizona, regulators emphasized facility-level manufacturing controls within large nutrition programs.
References
- https://wiky.com/2026/09/14/abbott-to-pay-384-million-over-contaminated-infant-formula-allegations-us-justice-dept-says/
- https://www.wndu.com/2026/09/14/abbott-agrees-pay-over-384-million-settle-contaminated-infant-formula-allegations/
- https://kelo.com/2026/09/14/abbott-to-pay-384-million-over-contaminated-infant-formula-allegations-us-justice-dept-says/
- https://kfgo.com/2026/09/14/abbott-to-pay-384-million-over-contaminated-infant-formula-allegations-us-justice-dept-says/